✦ LIBER ✦

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models

✍ Scribed by Tao, Leilei; Huang, Guichun; Shi, Shujing; Chen, Longbang

Book ID: 121577974
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 437 KB
Volume: 31
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-013-0777-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prospective study of the efficacy of a

A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients

✍ Zhong, Runbo; Han, Baohui; Zhong, Hua 📂 Article 📅 2013 🏛 S. Karger AG 🌐 English ⚖ 285 KB

Dendritic cell-activated cytokine-induce

Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery

✍ Li, Hui; Wang, Changli; Yu, Jinpu; Cao, Shui; Wei, Feng; Zhang, Weihong; Han, Yi 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 429 KB

Evaluating the Impact of Bevacizumab Mai

Evaluating the Impact of Bevacizumab Maintenance Therapy on Overall Survival in Advanced Non–Small-Cell Lung Cancer

✍ Dranitsaris, George; Beegle, Nancy; Ravelo, Arliene; Kalberer, Traci; Yu, Elaine 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 430 KB

Safety and efficacy of first-line bevaci

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

✍ Lucio Crinò; Eric Dansin; Pilar Garrido; Frank Griesinger; Janessa Laskin; Nick 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 204 KB

Preconditioning chemotherapy with paclit

Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model

✍ Xiang Huang; Guichun Huang; Haizhu Song; Longbang Chen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 718 KB

## Abstract Adoptive cell therapy involving the use of __ex vivo__ generated cytokine‐induced killer cells (CIKs) provides a promising approach to immunotherapy. However, the therapeutic activity of CIKs is limited by the immunosuppressive factors active in the host. It has become increasingly appa

9168 Safety and efficacy of first-line b

9168 Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SAiL study (MO19390)

✍ Dansin, E.; Tsai, C.M.; Pavlakis, N.; Laskin, J.; Griesinger, F.; Garrido, P.; C 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB